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Purpose: Longer term comparative efficacy information regarding transobtura-
tor and retropubic mid urethral slings is needed. We report 24-month continence
rates, complications and symptom outcomes from a randomized equivalence trial.
Materials and Methods: Primary outcomes were objective (negative stress test,
negative pad test and no re-treatment for stress urinary incontinence) and
subjective (no self-report of stress urinary incontinence symptoms, no leakage
episodes on 3-day bladder diary and no re-treatment for stress urinary inconti-
nence) success at 24 months. The predetermined equivalence margin was 12%.
Results: Of 597 randomized participants 516 (86.4%) were assessed. Objective
success rates for retropubic and transobturator mid urethral slings were 77.3%
and 72.3%, respectively (95% CI for difference of 5.1% was 2.0, 12.1), and
subjective success rates were 55.7% and 48.3%, respectively (CI for difference of
7.4% was 0.7, 15.5). Neither objective nor subjective success rates met the
prespecified criteria for equivalence. Patient satisfaction (retropubic 86.3% vs
transobturator 88.1%, p  0.58), frequency of de novo urgency incontinence
(retropubic 0% vs transobturator 0.3%, p  0.99) and occurrence of mesh expo-
sure (retropubic 4.4% vs transobturator 2.7%, p  0.26) were not significantly
different. The retropubic mid urethral sling group had higher rates of voiding
dysfunction requiring surgery (3.0% vs 0%, p  0.002) and urinary tract infec-
tions (17.1% vs 10.7%, p  0.025), whereas the transobturator group had more
neurological symptoms (9.7% vs 5.4%, p  0.045).
Conclusions: Objective success rates met the criteria for equivalence at 12
months but no longer met these criteria at 24 months. Subjective success rates
remained inconclusive for equivalence. Patient satisfaction remained high and
symptom severity remained markedly improved. Continued surveillance is im-
portant in women undergoing mid urethral sling surgery.
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most frequently used surgical procedures for stress
urinary incontinence in the United States and Eu-
rope.1,2 Two common approaches are used to place
the sling at the mid urethra. The sling is passed
transvaginally behind the pubic bone with the ret-
ropubic approach,3 whereas with the transobturator
approach it is passed laterally through the obturator
foramen to avoid the pelvic organs and vasculature
in the retropubic space.4 Recent meta-analyses of
randomized and quasi-randomized controlled trials
and prospective studies comparing the retropubic
with the transobturator approach suggest they have
a similar efficacy in the short term. However, the
studies considered were of insufficient quality to
permit definitive conclusions to be made about the
comparative efficacy and safety of these approaches
beyond 12 months.5–7
Based on the literature available when the
TOMUS (Trial Of Mid Urethral Slings) was de-
signed, we conducted an equivalence trial rather than
a superiority or noninferiority trial tomore definitively
state that the 2 MUS approaches were equivalent. We
previously reported 12-month success rates after sur-
gery in the TOMUS.8 Consistent with the original
design of the trial we report success rates, QOL, pa-
tient satisfaction, adverse events and other outcomes
of this clinical trial 24 months after surgery.
METHODS
We conducted a multicenter, randomized equivalence trial
of RMUS and TMUS surgery in women with SUI. Details
of the study design have been previously described.9
Women were eligible for the study if they were seeking
surgery for SUI, were 21 years old or older, had symptoms
of stress predominant UI and had a positive stress test at
a bladder volume of 300 ml or less. Two primary outcomes
of surgical success were assessed. Objective success was
defined as a negative provocative stress test at a bladder
volume of 300 cc or greater, a negative 24-hour pad test
and no re-treatment (behavioral, pharmacological or sur-
gical) for SUI. Subjective success was defined as the ab-
sence of self-reported symptoms of SUI on the MESA
(Medical, Epidemiological and Social Aspects of Aging)
questionnaire,10 no urine leakage on a 3-day voiding diaryand no re-treatment for SUI. Secondary outcomes in-
cluded complications/morbidity, self-report of QOL, symp-
tom bother, satisfaction and global improvement. Quality
of life was assessed by the IIQ (Incontinence Impact Ques-
tionnaire), with possible scores of 0 to 400, with higher
scores indicating a more negative impact on QOL.11 QOL
was also assessed by the ICIQ (International Consultation
on Incontinence Questionnaire), with possible scores of 0
to 21, with higher scores indicating a more negative im-
pact.12 Symptom bother was assessed by the UDI (Uro-
genital Distress Inventory), with possible scores of 0 to
300, with higher scores indicating greater distress.11 In
addition, participants completed the PGI-I (Patient Global
Impression of Improvement), a single item querying over-
all improvement, ranging from very much better to very
much worse.13 Adverse events, adjudicated by a group of
study investigators blinded to the surgical procedure,
were classified with a modification of the Dindo system.14
The study protocol was approved by an institutional review
board at each of the participating sites. Written informed
consent was obtained from each study participant. An inde-
pendent data and safety monitoring board reviewed the
progress, interim results and safety of the study.
With 250 women with available data in each group, it
was calculated that this study would have 80% power to
demonstrate equivalence between success rates in the 2
sling approaches (equivalence margin of 12 percentage
points) at a 2-sided significance level of 5%. The equiva-
lence margin was chosen for clinical considerations (eg
even if the 2 treatments differed by as much as 12 per-
centage points we would still be comfortable considering
the 2 arms equivalent) and practical considerations (eg
the number of patients suitable to enroll in the trial).
Generalized linear modeling, assuming a logit link and
binomial distribution, was used to calculate the rates of
treatment success. Equivalence for the primary outcome
was declared if the entire 95% CI for the difference be-
tween the 2 surgical approaches was within the equiva-
lence margin.
Only women who had undergone their assigned sur-
gery (per protocol) were included in the primary outcome
analysis. As in the primary TOMUS report, per protocol
analyses were used here to analyze the primary outcomes
because they provide more conservative estimates when
evaluating equivalence compared to intent to treat anal-
yses that may tend to bias toward concluding that the 2
arms are similar.8,15 We performed a secondary analysis
of the primary outcome and analyses of secondary out-
comes of women based on randomized assignment (intent
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months were calculated with the assumption that women
who were lost to followup were surgical successes since
these cases were assumed to be treatment successes until
treatment failures were reported. We performed sensitiv-
ity analyses by excluding women lost to followup and by
considering them cases of surgical failure. Fisher’s exact
test was used to compare the proportions of participants in
each group who had 1 or more AEs. Continuous outcomes
were analyzed by least squares modeling methods. Re-
peated measures modeling was used to assess changes by
treatment and/or time (visit) for relevant secondary out-
comes. No formal adjustment for multiple comparisons
was made. Analyses were performed with SAS® statisti-
cal software version 9.2.
RESULTS
The number of subjects screened for eligibility, ran-
domized and assessed at 12 and 24 months after
surgery is shown in figure 1. A total of 597 women
were randomized, and 552 (92.5%) and 516 (86.4%)
were assessed per protocol at 12 and 24 months,
respectively. The proportion of women who were
assessed per protocol at 24 months or of those in
whom surgery failed during that time was similar in
the retropubic and transobturator groups at 253
(84.9%) and 263 (88.0%), respectively.
Baseline demographic and clinical characteristics
were similar in both surgery groups (data not
shown) except for Valsalva leak point pressure,
Screened for eligibility
(n=3521)
Provided written consent
(n=749)
Randomized
(n=597)
Assigned to Retropubic
(n=298)
Assigned to Transobturator
(n=299)
Followed-up for treatment success at 
12 months (n=274)
Lost to followup (n=8)
Withdrew consent (n=7)
Other (n=2)
Followed-up for treatment success at 12 
months (n=278)
Lost to followup (n=8)
Withdrew consent (n=5)
Other (n=1)
Followed-up for treatment success at 24 
months (n=253)
Lost to followup (n=10)
Withdrew consent (n=3)
Other (n=8)
Followed-up for treatment success at 
24 months (n=263)
Lost to followup (n=7)
Withdrew consent (n=5)
Other (n=3)
Not included in PP analysis (n=7)
    Ineligible (n=4)
    Crossover and ineligible (n=1)
    Did not receive study surgery (n=2)
Included in PP 
analysis
(n=291)
Included in PP 
analysis
(n=292)
Not included in PP analysis (n=7)
    Ineligible (n=6)
    Crossover (n=1)
Figure 1. Study enrollment, randomization and assessment. PP,
per protocol.which was lower in the retropubic arm than in the
transobturator arm (mean  SD 114.4  43.1 vs
124.2  41.4 cm H2O, respectively, p  0.03).
8 Mean
age of the study participants was 53 years ( 11).
Both groups had a median of 2.7 incontinence epi-
sodes per day and a median of 12.5 gm urine loss
measured on a 24-hour pad test. There were 79
women (13%) who reported a prior surgery for UI.
The frequency of concomitant surgery was similar in
the retropubic and transobturator arms (25% and
26%, respectively).
The unadjusted 24-month objective success rate
for the retropubic and transobturator sling was
77.3% and 72.3%, respectively (95% CI for difference
of 5.1% was 2.0%, 12.1%), while the subjective
success rate was 55.7% and 48.3%, respectively (95%
CI for difference of 7.4% was0.7%, 15.5%). Neither
the objective nor the subjective success rates met the
prespecified criteria for equivalence. However, each
of the confidence intervals included 0%, indicating
that the success rates also cannot be considered
different from one another (fig. 2). These rates did
not change significantly after statistical adjustment
for clinical center, concomitant surgery, and the uro-
dynamic measures of Valsalva leak point pressure
and maximal urethral closure pressure, or when
study participants lost to followup were considered
cases of surgical failure or were excluded from anal-
ysis. The proportion of women in whom treatment
failed at 24 months by the individual components of
the primary outcomes is shown in figure 3. Note that
failure could occur in a woman by more than 1
criterion.
During 24 months of followup 75 SAEs were iden-
tified in 70 women. The rate in the retropubic arm
(15.1%) was approximately twice that in the trans-
obturator arm (8.4%), primarily as a result of more
intraoperative bladder injuries. Of the 75 SAEs re-
ported 12 (16.0%) occurred 12 to 24 months after
surgery (4 in the retropubic arm and 8 in transob-
turator arm). A total of 308 adverse events were
experienced by 219 women during the 24 months
after surgery. The rate was 40.6% (174 AEs in 121
women) in the retropubic arm and 32.8% (134 AEs
in 98 women) in the transobturator arm (see table).
Of the 308 AEs 43 (14.0%) occurred between 12 and
24 months (27 in the retropubic arm and 16 in the
transobturator arm).
When SAEs and AEs were combined by complica-
tion type, rates of de novo urgency incontinence (0%
vs 0.3%, p 0.99), persistent urgency incontinence
(14.1% vs 12.7%, p  0.63) and mesh exposure (4.4%
vs 2.7%, p 0.26) were similar in the retropubic and
transobturator groups, respectively. However, the
retropubic group had higher rates of voiding dys-
function requiring surgery (3.0% vs 0%, p  0.002)
and UTIs (17.4% vs 10.7%, p  0.018), while the
retrop
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ical symptoms (9.7% vs 5.4%, p  0.045).
Similarly, high rates of patient satisfaction were
observed in the retropubic and transobturator groups
at 24 months (86.3% vs 88.1%, respectively, p  0.58,
fig. 4, A). However, the proportion of women who
reported being much or very much better on the
PGI-I at 24 months was higher in the transobturator
group (91.5%) than in the retropubic group (86.8%)
(p  0.02, fig. 4, B). Based on repeated measures
modeling of QOL measures, neither the change from
Figure 2. Objective and subjective success rates with 95% CIs for
Figure 3. Proportion of failure of individual components of objec-
tive and subjective outcomes by surgery group. Note that treat-
ment in women could fail by more than 1 individual component.baseline in total UDI scores (retropubic -100 vs trans-
obturator -107, p  0.13) nor in total IIQ scores
(retropubic - 125 vs transobturator - 124, p  0.89)
differed by treatment group.
DISCUSSION
This report extends our previous findings from a
multicenter equivalence trial of RMUS and TMUS
by following study participants up to 24 months
after surgery. While objective and subjective success
rates for both approaches decreased modestly from
12 to 24 months after surgery, these decreases re-
flect a continued trend of greater benefit with the
retropubic than with the transobturator mid ure-
thral sling. The decrease in objective success rates
during that period resulted in not meeting our pre-
specified criteria for equivalence of the 2 approaches
at 24 months. This finding is in contrast to our
previous report at 12 months of clinical and statis-
tical equivalence of objective success rates for the
retropubic and transobturator approaches.8 Similar
to the 12-month findings, the subjective success
rates also did not reach the predetermined criteria
for equivalence at 24 months. Despite the decrease
in objectively and subjectively assessed success
rates, study participants from both surgical groups
reported a high level of satisfaction as well as im-
provements in urinary symptom severity and QOL
24 months after surgery.
As previously noted, the decrease in success rates
ubic and transobturator mid urethral slings at 12 and 24 monthsalso led to a widening difference between the trans-
TREATMENT SUCCESS OF MID URETHRAL SLINGS 2285Adverse events by treatment group, severity and system up to 2 years
Retropubic (298) Transobturator (299)
p Value†Total Events
No. Events in
13–24 Mos
No. Unique Pts
(%)* Total Events
No. Events in
13–24 Mos
No. Unique Pts
(%)*
Grades III–IV, requiring surgical, endoscopic or radiological intervention
Wound: 11 1 10 (3.4) 11 6 11 (3.7) 0.99
Mesh exposure‡ 10 1 9 (3.0) 6 5 6 (2.0) 0.45
Mesh erosion§ 1 0 1 (0.3) 1 0 1 (0.3)
Surgical site infection 0 0 0 (0) 3 1 3 (1.0)
Granulation tissue 0 0 0 (0) 1 0 1 (0.3)
Genitourinary: 25 2 25 (8.4) 13 0 13 (4.3) 0.046
Urethral perforation 1 0 1 (0.3) 0 0 0 (0)
Bladder perforation 15 0 15 (5.0) 0 0 0 (0)
Vaginal epithelial perforation 6 0 6 (2.0) 13 0 13 (4.3)
Recurrent cystitis 3 2 3 (1.0) 0 0 0 (0)
Vascular/hematological: 1 0 1 (0.3) 1 0 1 (0.3) 0.99
Pulmonary embolus 0 0 0 (0) 1 0 1 (0.3)
Postop bleeding 1 0 1 (0.3) 0 0 0 (0)
Neurological symptoms¶ 1 0 1 (0.3) 0 0 0 (0) 0.50
Voiding dysfunction requiring surgery 9 1 9 (3.0) 0 0 0 (0) 0.002
Pain per pt self-report 6 wks or more** 0 0 0 (0) 0 0 0 (0) Not available
Other 0 0 0 (0) 3 2 3 (1.0) 0.25
Overall SAEs 47 4 45 (15.1) 28 8 25 (8.4) 0.011
Grades I–II, expectant or pharmacological intervention
Wound: 6 0 6 (2.0) 2 3 2 (0.7) 0.18
Mesh exposure‡ 4 0 4 (1.3) 2 1** 2 (0.7)
Mesh erosion§ 0 0 0 (0) 0 0 0 (0)
Surgical site infection 2 0 2 (0.7) 0 2†† 0 (0)
Genitourinary: 61 15 51 (17.1) 35 8 32 (10.7) 0.025
Cystitis - culture proven 27 4 25 (8.4) 16 1 14 (4.7)
Cystitis - empirically treated 16 1 15 (5.0) 9 1 9 (3.0)
Recurrent cystitis 18 10 16 (5.4) 10 6 10 (3.3)
Vascular/hematological: 20 0 18 (6.0) 7 0 7 (2.3) 0.026
Pulmonary embolus 0 0 0 (0) 0 0 0 (0)
Intraop bleeding 14 0 14 (4.7) 7 0 7 (2.3)
Postop bleeding 6 0 5 (2.0) 0 0 0 (0)
Neurological symptoms:¶ 20 5 15 (5.0) 32 1 29 (9.7) 0.041
Numbness 9 1 6 (2.0) 9 1 7 (2.3)
Weakness 11 4 10 (3.4) 23 0 22 (7.4)
Voiding dysfunction: 10 0 10 (3.4) 6 2 6 (2.0) 0.33
Managed with catheter only 6 0 6 (2.0) 4 2 4 (1.3)
Managed with prescription drug only 2 0 2 (0.7) 1 0 1 (0.3)
Managed with behavioral treatment or
neuromodulation ( catheter)
2 0 2 (0.7) 1 0 1 (0.3)
Pain per pt self-report 6 wks or more‡‡ 7 0 7 (2.3) 7 0 6 (2.0) 0.79
Prescription for persistent urgency incontinence§§ 42 6 42 (14.1) 38 8 38 (12.7) 0.63
Other 8 1¶¶ 7 (2.3) 6 0 6 (2.0) 0.79
Overall AEs‡‡ 174 27 121 (40.6) 134 16 98 (32.8) 0.051
One subject randomized to the retropubic procedure underwent transobturator sling surgery and had culture proven cystitis (1 of the 23 in retropubic arm). One subject
randomized to the transobturator procedure underwent a retropubic procedure and had no SAEs or AEs.
Adverse event defined as a deviation from the normal intraoperative or postoperative course (grades I and II). A single patient can have multiple entries.
Severity grade determined by a slightly modified version of Dindo14 classification system based on level of therapy required to treat an event. SAE defined as grade III to
V. No grade IV or V events occurred in either group. Grade I—no pharmacological, surgical or radiological intervention (allowed therapeutic regimens include antiemetics,
antipyretics, analgesics, diuretics, electrolytes and physiotherapy). Grade II—requires pharmacological treatment with drugs other than those allowed for grade I
complications (antibiotics, blood transfusions and total parenteral nutrition included). Grade III—requires surgical, endoscopic or radiological intervention. Grade IV—life
threatening complication requiring intensive care management. Grade V—death.
* Number of patients with a particular AE (less than or equal to the number of events). The percent equals the number of unique patients with an AE divided by the number
of patients in the treatment group.
† Calculated from Fisher’s exact tests comparing the number of unique patients with events by treatment group using the total number of patients as denominators.
‡ Defined as mesh visualized in the vagina through a prior incision area with or without an inflammatory reaction.
§ Defined as erosion after primary healing into an organ or surrounding tissue.
 Defined as presumed UTI with treatment, 3 or more infections in 1 year after 6-week visit.
t arm
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months. The difference in objective success rates
increased from 3% to 5.1% while the difference in
subjective success rates increased from 6.4% to
7.1%, both in favor of the retropubic approach. A
recent Cochrane review comparing retropubic and
transobturator mid urethral slings demonstrated sub-
jective cure rates of 83% with no statistically signifi-
cant difference in subjective cure and improvement
rates between the 2 approaches at 12 months. How-
ever, longer followup was not available.5 An updated
review of surgery for SUI conducted by Novara et al
demonstrated similar subjective efficacy rates and a
trend toward higher objective efficacy in the retropubic
group, similar to our findings.7
The use of composite outcomes to define treatment
success, such as those in the TOMUS, has been shown
to result in lower success rates compared to a single
outcome measure used in many previous studies com-
paring the efficacy of mid urethral slings.16–18 This
may explain the relatively low success rates we ob-
served at 12 and 24 months after surgery. Our ap-
proach of including objective and subjective out-
comes is reasonable given the recent emphasis on
¶ Defined as patient self-report on standardized form of new paresthesias or alteration
or weakness was ascertained by the patient marking a body map. There were 3 neuro
numbness and 1 of upper leg weakness. The neurological SAE in the transobturator
** There were 3 reported mesh exposure AEs at the 12-month visit and 2 at the 2
were reclassified as mesh exposure SAEs at the 24-month visit, 1 was previousl
†† There were 2 reported surgical site infection AEs at the 12-month visit and 0 rep
site infections were reclassified at the 24-month visit as a mesh exposure SAE
‡‡ Defined as self-report at or beyond 6 weeks after surgery by patient answerin
a result of your incontinence operation?” and patient answering any of the first 3
mm total length) and patient answering the bother question on the McCarthy vis
§§ De novo urgency UI defined as baseline pure SUI in patient at or beyond 6-w
initiated treatment with anticholinergic medication for urgency UI. Persistent u
sometimes or often, and/or having initiated treatment with anticholinergics for u
 Other AEs include granulation tissue, pyelonephritis, pelvic pain not associated
vaginal cuff from hysterectomy/suspension, medication reaction, bilobed fluid fill
¶¶ There were 2 new other events that occurred between the 12 and 24-month v
Figure 4. A, mean total UDI and percent satisfied vs time by tre
improved or very much improved on PGI-I vs time by treatmenAE at 12 months. Thus, net change was only 1 additional other AE.patient centered and other domains to assess surgi-
cal success for UI. When individual components of
the primary outcomes were considered, rates of fail-
ure by stress testing and stress symptoms on the
MESA were higher in the transobturator arm than
in the retropubic arm, suggesting the possibility of
superior continence rates with the RMUS approach,
consistent with the trends seen in overall treatment
success. Similar to several prior reports, success
rates varied in our study depending on the outcome
measure used.17,18
During 24 months the AE profile differed signifi-
cantly between the 2 surgical approaches. With re-
spect to specific AEs, intraoperative bladder perfo-
rations, postoperative voiding dysfunction requiring
surgical intervention and UTIs each occurred more
frequently in the retropubic group, whereas groin
and lower extremity neurological symptoms were
more commonly observed in the transobturator
group. These findings are similar to conclusions re-
ported in a recent systematic review and meta-anal-
ysis.7 The longer term followup informs clinicians
and patients about the continued occurrence of
known complications over time.
r function that developed between surgery and 6-week visit. The location of numbness
AEs in the retropubic arm with 1 report of lower leg numbness, another of upper leg
upper leg numbness. Neurological AEs were listed by location.
visit, so the difference was 1. On closer examination, 2 of the mesh exposures
ed at 12 months and 1 was new at the 24-month visit.
the 24-month visit, so the difference was2. On closer examination, both surgical
s a surgical site infection SAE (I).
o the introductory question, “Have you had any pain within the last 24 hours as
hy pain questions at a level of 75 mm or greater on the visual analog scale (150
log scale at a level of 75 mm or greater.
t now answering any MESA10 urge question sometimes or often, and/or having
I defined as baseline mixed UI in patient answering any MESA urge question
I.
, anxiety, thrush, urinary tract colonization, wound edge separation, minor wound,
nd skin irritation.
d 1 event that was reclassified as a neurological AE at 24 months from an other
t arm during 24 months. B, mean ICIQ score and percent much
during 24 months.in moto
logical S
arm was
4-month
y report
orted at
(I) and a
g yes t
McCart
ual ana
eek visi
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rgency U
with UTI
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garding complications from mesh products used in
contemporary surgical procedures for SUI during a
2-year period. Our study included a standardized pel-
vic examination at 24 months to evaluate mesh com-
plications. The overall rates of mesh exposure did not
differ significantly by treatment group at 24 months.
Also, the number of mesh exposures identified in the
first year after surgery was higher in the retropubic
group, whereas in the 13 to 24-month period more
mesh exposures were seen in the transobturator
group, highlighting the need for long-term clinical fol-
lowup of patients undergoing mid urethral sling sur-
gery. Others have also reported on the later presenta-
tion of mesh complications.6,19 Our report is especially
timely given the recent warnings from the Food and
Drug Administration about the use of mesh products
in pelvic floor and incontinence surgical procedures.20
This study has several strengths. Objective and
subjective measures of surgical success were used to
capture a broad spectrum of outcomes. Rates of par-
ticipant assessment 2 years after surgery were high
and did not vary significantly by surgery group. Com-
plications of surgery were assessed in a standardized
manner with standardized definitions across sites.
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